Another research indicates that immunotherapy combined with blockade of PD-L1 and CCL-5 may provide an effective treatment for patients with pancreatic ductal adenocarcinomas (PDAC) with high cancer Forkhead box protein 3 (Cancer-FOXP3 or C-FOXP3) levels (94). The gene discussed is FOXP3; the disease is pancreatic ductal adenocarcinoma.